ICON is a clinical research organization that provides outsourced development and commercialization services across the drug and medical device development lifecycle. The company specializes in managing clinical trials and supporting regulatory pathways from early compound selection through Phase I-IV studies and post-approval commercialization. ICON serves pharmaceutical, biotechnology, and medical device companies, along with government and public health organizations across multiple geographies.
The company operates across several service lines, including clinical development and trial management, laboratory services (encompassing bionanalytical, biomarker, vaccine, and central laboratory functions), and commercial services focused on development strategy and post-market positioning. ICON also offers specialized solutions in areas such as cardiac safety, medical imaging, decentralized trial execution, and real-world intelligence gathering, alongside site access and patient recruitment services.
With approximately 39,800 full-time employees, ICON operates internationally with significant presence in the United States, Europe, and other regions. The company is headquartered in Dublin, Ireland and maintains a market capitalization of $8.6 billion. As a Nasdaq-listed entity, ICON competes within the broader contract research organization sector, which supports outsourced drug development activities for its customer base.
No 10-K filings found.